Pearl River Capital, LLC Alkermes Plc. Transaction History

Pearl River Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$26.4 - $32.56 $59,558 - $73,455	-2,256 Reduced 7.15%	29,298 $793,000
Q4 2023 Feb 13, 2024	SELL	$23.37 - $28.68 $369,900 - $453,947	-15,828 Reduced 33.41%	31,554 $875,000
Q3 2023 Nov 13, 2023	BUY	$27.17 - $31.97 $754,619 - $887,934	27,774 Added 141.65%	47,382 $1.33 Million
Q2 2023 Aug 11, 2023	BUY	$28.34 - $33.63 $555,690 - $659,417	19,608 New	19,608 $613,000
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $5,500 - $7,967	250 Added 1.66%	15,323 $342,000
Q2 2022 Aug 12, 2022	SELL	$26.4 - $30.54 $6,652 - $7,696	-252 Reduced 1.64%	15,073 $449,000
Q1 2022 May 13, 2022	BUY	$23.07 - $27.99 $21,408 - $25,974	928 Added 6.45%	15,325 $403,000
Q4 2019 Feb 12, 2020	BUY	$17.29 - $21.74 $248,924 - $312,990	14,397 New	14,397 $294,000

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.73B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Pearl River Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pearl River Capital, LLC with notifications on news.